News >

Leveraging Limited Data in Metastatic Pancreatic Cancer

Caroline Seymour
Published: Thursday, Mar 21, 2019

Damian Laber, MD

Damian Laber, MD

Although both regimens carry added toxicities, FOLFIRINOX and the combination of gemcitabine and nab-paclitaxel (Abraxane) have each been shown to improve survival over gemcitabine alone for patients with metastatic pancreatic cancer, said Damian Laber, MD.

State of the Science Summit™ on Gastrointestinal Malignancies, Laber, hematologist/oncologist and senior member of Moffitt Cancer Center, provided a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shared his hope for the future of the treatment paradigm.

OncLive: Could you discuss the trials that led to current frontline approaches?

Laber: It took many years [to establish FOLFIRINOX as a frontline treatment for patients with metastatic pancreatic cancer]. In 2011, a study was published comparing gemcitabine with FOLFIRINOX; patients in that study had not received prior chemotherapy. They had to have locally advanced or metastatic disease and were not candidates for curative therapy; the randomization was done fairly well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication